Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022

Publisher Name :
Date: 27-Jul-2017
No. of pages: 236
Inquire Before Buying

“Global overactive bladder treatment market is projected to grow at a CAGR of 2.9%.”

The global overactive bladder treatment market is estimated to grow at a CAGR of 2.9% from 2017 to 2022, to reach USD 4.19 billion by 2022. The key factors driving the growth of this market include the rising prevalence of overactive bladder (OAB) coupled with the growing geriatric population and rising neurological disorders, namely, Parkinson’s Disease (PD), stroke, and multiple sclerosis (MS). However, the undesired systemic effects of current OAB treatments may hinder the growth of the market to a certain extent during the forecast period.

“The neurostimulation and BOTOX treatment segments are expected to grow at the highest CAGR.”

On the basis of pharmacotherapy, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. The neurostimulation and BOTOX treatment segments are expected to witness the highest growth during the forecast period. The growth of these segments is mainly due to the higher efficacy and longevity of the treatment effects as compared to anticholinergics.

“The solifenac in to dominate the global overactive bladder treatment market during the forecast period.”

Based on anticholinergic drugs, the overactive bladder treatment market is further classified into darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium, and other anticholinergics (imidafenacin, emepronium, flavoxate, meladrazine, terodiline, propiverine, and desfesoterodine). Solifenacin is expected to command for the largest share of the global overactive bladder treatment market owing to its efficacy as compared to other drugs of its class.

“RoAPAC to witness the highest growth during the forecast period (2017-2022)”

The U.S.held the largest share of the global overactive bladder treatment market in 2016, while the Rest of Asia-Pacific (RoAPAC) is expected to witness the highest growth during 2017 to 2022. Growing healthcare expenditure in countries like India, China, and Singapore; favorable demographics; and aggressive marketing by pharma companies leading to rising awareness on OAB are the key factors responsible for the growth of this market in the Ro APAC region.

Break of primary participants was as mentioned below:


  • By Company Type – Tier 1–60%, Tier 2–25% and Tier 3–15%

  • By Designation – C-level–17%, Director Level–45%, Others–38%

  • By Region – North America–42%, Europe–28%, Asia-Pacific–17%, RoW–13%


Some of the major market players in the overactive bladder treatment market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co.,Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).

Research Coverage:

The report analyzes the overactive bladder treatment market and aims at estimating the market size and future growth potential of this market based on various segments such as pharmacotherapy, disease type, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would helpthem, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:


  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global overactive bladder treatment market. The report analyzes the global overactive bladder treatment market by pharmacotherapy, disease type, and region.

  • Product Innovation: Detailed insights on upcoming trends and new product launches in the global overactive bladder treatment market

  • Market Development: Comprehensive information on the lucrative emerging markets by pharmacotherapy, disease type, and region

  • Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global overactive bladder treatment market

  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and drugs in pipeline of leading players in the global market.

Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022

Table of Contents

1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered in the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
1.7 Assumptions

2 Research Methodology
2.1 Research Methodology Steps
2.2 Research Design
2.3 Market Size Estimation
2.4 Data Triangulation Methodology
2.5 Market Share Estimation
2.5.1 Key Data Points Taken From Secondary Sources
2.5.2 Key Data Points Taken From Primary Sources
2.5.2.1 Key Industry Insights

3 Executive Summary

4 Market Overview
4.1 Introduction
4.2 Drivers
4.2.1 Development of Innovative Intravesical Therapies
4.2.2 Aggressive Marketing By Pharma Companies
4.2.3 Aging Population and Rising Incidence of Diseases Characterized By OAB
4.3 Restraints
4.3.1 Undesired Systemic Effects of Current OAB Treatments
4.4 Opportunities
4.4.1 Novel Treatments, Robust Pipeline, and Patent Cliff of Certain Drugs
4.5 Challenges
4.5.1 Lack of Awareness on OAB

5 Global Overactive Bladder Treatment Market, By Pharmacotherapy
5.1 Introduction
5.2 Anticholinergics
5.2.1 Solifenacin
5.2.2 Oxybutynin
5.2.3 Fesoterodine
5.2.4 Darifenacin
5.2.5 Tolterodine
5.2.6 Trospium
5.2.7 Other Anticholinergics
5.3 Mirabegron
5.4 Botox
5.5 Neurostimulation
5.6 Intravesical Instillation

6 Global Overactive Bladder Treatment Market, By Disease
6.1 Introduction
6.2 Idiopathic Overactive Bladder
6.3 Neurogenic Overactive Bladder
6.3.1 Introduction
6.3.2 Overactive Bladder in Parkinson's Disease
6.3.3 Overactive Bladder in Stroke
6.3.4 Overactive Bladder in Multiple Sclerosis
6.3.5 Overactive Bladder in Spinal Cord Injury
6.3.6 Overactive Bladder in Other Disorders

7 Global Overactive Bladder Treatment Market, By Region
7.1 Introduction
7.2 U.S.
7.2.1 Favorable Reimbursement
7.2.2 Strong Pharma Industry and Significant Marketing Efforts
7.2.3 Favorable Demographics of Population at Risk
7.2.4 Initiatives to Increase Awareness on OAB
7.3 Europe
7.3.1 Introduction
7.3.2 EU-5
7.3.2.1 Industry Dynamics
7.3.2.2 Demographics and OAB Prevalence
7.3.2.3 Attractive Healthcare Sector
7.3.2.4 Favorable Reimbursement Policies
7.3.2.5 Other Factors
7.3.3 Rest of Europe
7.4 Asia-Pacific
7.4.1 Introduction
7.4.2 Japan
7.4.3 Rest of Asia-Pacific
7.5 Rest of the World (RoW)

8 Marketed Products
8.1 Marketed Products for Overactive Bladder Syndrome in the U.S.
8.2 Marketed Products for Overactive Bladder Syndrome in EU-5

9 Pipeline Products
9.1 Pipeline Products for Overactive Bladder Syndrome in the U.S.
9.2 Pipeline Products for Overactive Bladder Syndrome in EU-5

10 Drug Profiles
10.1 Darifenacin
10.2 Fesoterodine
10.3 Oxybutynin
10.4 Solifenacin
10.5 Tolterodine
10.6 Trospium
10.7 Injection Botox

11 Company Profiles
(Overview, Strength of Product Portfolio Business Strategy Excellence Products Offering, Recent Development’s, Business Strategy)*
11.1 Astellas Pharma Inc.
11.2 Pfizer, Inc.
11.3 Teva Pharmaceutical Industries Limited
11.4 Allergan, PLC.
11.5 Mylan N.V.
11.6 Endo International PLC
11.7 Hisamitsu Pharmaceutical Co., Inc.
11.8 Sanofi
11.9 Aurobindo Pharma Limited
11.10 Johnson & Johnson
11.11 Intas Pharmaceuticals Ltd.
11.12 Apotex Inc.
11.13 Macleods Pharmaceuticals Ltd.
11.14 Medtronic PLC
11.15 Cogentix Medical, Inc.

*Details on Overview, Strength of Product Portfolio Business Strategy Excellence Products Offering, Recent Development’s, Business Strategy Might Not Be Captured in Case of Unlisted Companies.

12 Appendix
12.1 Insights of Industry Experts
12.2 Discussion Guide
12.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.4 Introducing RT: Real-Time Market Intelligence
12.5 Available Customizations
12.6 Related Reports
12.7 Authors Details

List of Tables

Table 1 Global Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 2 Indicative List of Anticholinergics Used in OAB Treatment
Table 3 Global Anticholinergics Market for Overactive Bladder Treatment, 2015–2022 (USD Million)
Table 4 Global Anticholinergics Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 5 Solifenacin Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 6 Oxybutynin Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 7 Fesoterodine Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 8 Darifenacin Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 9 Tolterodine Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 10 Trospium Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 11 Other Anticholinergics Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 12 Mirabegron Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 13 Botox Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 14 Neurostimulation Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 15 Global Overactive Bladder Treatment Market, By Disease Type, 2015–2022 (USD Million)
Table 16 Global Idiopathic Overactive Bladder Treatment Market, By Country/Region, 2015–2022 (USD Million)
Table 17 Global Neurogenic Overactive Bladder Treatment Market, By Disease, 2015–2022 (USD Million)
Table 18 Global Neurogenic Overactive Bladder Treatment Market, By Country/Region, 2015–2022 (USD Million)
Table 19 Global Market for Parkinson’s Disease, By Country/Region, 2015–2022 (USD Million)
Table 20 Global Market for Stroke, By Country/Region, 2015–2022 (USD Million)
Table 21 Global Market for Multiple Sclerosis, By Country/Region, 2015–2022 (USD Million)
Table 22 Global Market for Spinal Cord Injuries, By Country/Region, 2015–2022 (USD Million)
Table 23 Global Market for Other Disorders, By Country/Region, 2015–2022 (USD Million)
Table 24 Overactive Bladder Treatment Market, By Country/Region, 2015–2022 (USD Million)
Table 25 U.S.: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 26 U.S. Market, By Disease Type, 2015–2022 (USD Million)
Table 27 Europe: Overactive Bladder Treatment Market, By Country/Region, 2015–2022 (USD Million)
Table 28 Europe: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 29 Europe: Market, By Disease Type, 2015–2022 (USD Million)
Table 30 EU-5: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 31 EU-5: Market, By Disease Type, 2015–2022 (USD Million)
Table 32 RoE: Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 33 RoE: Market, By Disease Type, 2015–2022 (USD Million)
Table 34 APAC: Market, By Country/Region, 2015–2022 (USD Million)
Table 35 APAC: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 36 APAC: Market, By Disease Type, 2015–2022 (USD Million)
Table 37 Japan: Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 38 Japan: Market, By Disease Type, 2015–2022 (USD Million)
Table 39 RoAPAC: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 40 RoAPAC: Market, By Disease Type, 2015–2022 (USD Million)
Table 41 RoW: Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 42 RoW: Market, By Disease Type, 2015–2022 (USD Million)
Table 43 U.S.: Marketed Products in Global Market
Table 44 EU-5: Marketed Products in Global Market
Table 45 U.S.: Pipeline Products in Global Market
Table 46 EU-5: Pipeline Products in Global Market
Table 47 Drug Profile: Darifenacin
Table 48 Drug Profile: Fesoterodine
Table 49 Drug Profile: Oxybutynin
Table 50 Drug Profile: Solifenacin
Table 51 Drug Profile: Tolterodine
Table 52 Drug Profile: Trospium
Table 53 Drug Profile: Botox (Onabotulinumtoxina)

List of Figures

Figure 1 Overactive Bladder Treatment Market
Figure 2 Years Considered for Study – 2017: Estimated Year, 2022: Projected Year
Figure 3 Research Methodology: Secondary Research, Primary Research, and Market Breakdown Steps
Figure 4 Research Design
Figure 5 Secondary Research
Figure 6 Market Size (USD) Estimation Methodology
Figure 7 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 8 Data Triangulation Methodology
Figure 9 Overactive Bladder Treatment: Market Overview (USD Billion)
Figure 10 Global Overactive Bladder Treatment Market, By Pharmacotherapy (USD Million)
Figure 11 Global Market, By Disease Type (USD Million)
Figure 12 Global Neurogenic Overactive Bladder Treatment Market, By Diseases (USD Million)
Figure 13 Geographical Snapshot of the Global Market
Figure 14 Global Market: Drivers, Restraints, Opportuniities, and Challenges
Figure 15 Geriatric Population (Aged 60 and Above) Percentage in 2015 & 2030
Figure 16 Overactive Bladder Treatment Market Segmentation By Pharmacotherapy
Figure 17 Overactive Bladder Diagnosis and Treatment
Figure 18 Global Market Segmentation By Disease Type
Figure 19 Estimated OAB Prevalence in the U.S. and EU-5 (2015)
Figure 20 Prevalence of MS Per 100,000 Individuals
Figure 21 Overactive Bladder Treatment Market in RoAPAC to Grow at the Highest Rate (2017–2022)
Figure 22 U.S.: Branded vs Generic Prescription Drug Revenues (2011-2016)
Figure 23 U.S.: Elderly Population (Aged 65 Years and Above)
Figure 24 U.S.: Obese Population (BMI ≥ 30)
Figure 25 U.S.: National Health Expenditure as % of GDP
Figure 26 Germany Healthcare Expenditure as A % of GDP
Figure 27 Italy: Public and Private Healthcare Spending
Figure 28 Astellas Pharma, Inc.: Company Snapshot (2016)
Figure 29 Pfizer, Inc.: Company Snapshot (2016)
Figure 30 Teva Pharmaceutical Industries Limited: Company Snapshot (2016)
Figure 31 Allergan, PLC: Company Snapshot (2016)
Figure 32 Mylan N.V.: Company Snapshot (2016)
Figure 33 Endo International PLC: Company Snapshot (2016)
Figure 34 Hisamitsu Pharmaceutical Co., Inc.: Company Snapshot (2015)
Figure 35 Sanofi: Company Snapshot (2016)
Figure 36 Aurobindo Pharma Limited: Company Snapshot (2015)
Figure 37 Johnson & Johnson: Company Snapshot (2016)
Figure 38 Medtronic PLC: Company Snapshot (2016)
Figure 39 Cogentix Medical, Inc.: Company Snapshot (2016)

  • 2017-2022 Europe Top Countries Vegetarian Softgel Capsules Market Report
    Published: 17-Oct-2017        Price: US 4660 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Europe Vegetarian Softgel Capsules market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Vegetarian Softgel Capsules in Europe market, especially in Germany, UK, France, Italy, Russia, Benelux, Turkey and other countries in Europe, focuses on the top players in each country, cov......
  • 2017-2022 North America Vegetarian Softgel Capsules Market Report
    Published: 17-Oct-2017        Price: US 4660 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the North America Vegetarian Softgel Capsules market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Vegetarian Softgel Capsules in North America market, especially in United States, Canada and Mexico, focuses on the top players in each country, covering - Catalent - Pr......
  • 2017-2022 United States Vegetarian Softgel Capsules Market Report (Status and Outlook)
    Published: 17-Oct-2017        Price: US 3360 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Vegetarian Softgel Capsules market size was xx million USD in United States, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In United States market, the top players include - Catalent - Procaps Laboratorios - EuroCaps - Best Formulations - Aenova - Captek - SIRIO - Bahr......
  • 2017-2022 Global Top Countries Vegetarian Softgel Capsules Market Report
    Published: 17-Oct-2017        Price: US 4960 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the global Vegetarian Softgel Capsules market size was xx million USD, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Vegetarian Softgel Capsules in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Mi......
  • 2017-2022 India Vegetarian Softgel Capsules Market Report (Status and Outlook)
    Published: 17-Oct-2017        Price: US 3360 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Vegetarian Softgel Capsules market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In India market, the top players include - Catalent - Procaps Laboratorios - EuroCaps - Best Formulations - Aenova - Captek - SIRIO - Bahrain Pharma......
  • 2017-2022 China Vegetarian Softgel Capsules Market Report (Status and Outlook)
    Published: 17-Oct-2017        Price: US 3360 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Vegetarian Softgel Capsules market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include - Catalent - Procaps Laboratorios - EuroCaps - Best Formulations - Aenova - Captek - SIRIO - Bahrain Pharma - Robi......
  • 2017 Top 5 Vegetarian Softgel Capsules Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 17-Oct-2017        Price: US 4960 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." The Global Vegetarian Softgel Capsules market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Vegetarian Softgel Capsules market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top ......
  • 2017-2022 Asia-Pacific Top Countries Vegetarian Softgel Capsules Market Report
    Published: 17-Oct-2017        Price: US 4660 Onwards        Pages: 121
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Asia-Pacific Vegetarian Softgel Capsules market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Vegetarian Softgel Capsules in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and Philippines, focuses on the top players in each......
  • Global Blood Group Typing Market Size, Status and Forecast 2022
    Published: 16-Oct-2017        Price: US 3300 Onwards        Pages: 95
    This report studies the global Blood Group Typing market, analyzes and researches the Blood Group Typing development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Bio-Rad Laboratories, Inc. - Grifols, S.A. - Immucor, Inc. - Merck Millipore - Ortho Clinical Diagnostics, Inc. - Bag Health Care GmbH - Danaher Corporation - Quotient, Ltd. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs